Results 91 to 100 of about 97,135 (282)
A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia
Pediatric Blood &Cancer, EarlyView.ABSTRACT
A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering +10 morewiley +1 more sourceGemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors
Pediatric Blood &Cancer, EarlyView.ABSTRACT
Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh +10 morewiley +1 more sourceCPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background/Objectives
Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis +17 morewiley +1 more sourceNovel Genetic Risk Factor Identified for L‐Asparaginase‐Induced Pancreatitis in Pediatric Patients With Cancer
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background
L‐asparaginase is a critical component in treatment protocols for pediatric acute lymphoblastic leukemia. Acute pancreatitis reactions can necessitate delays and, in some cases, discontinuation of L‐asparaginase, which compromises outcomes.Edward J. Raack, Wan‐Chun Chang, Miguel Cordova‐Delgado, Spencer J. Anderson, Jessica N. Trueman, Erika N. Scott, Catrina M. Loucks, Shahrad R. Rassekh, Gabriella S. S. Groeneweg, Michelle Higginson, Kathy Li, Fudan Miao, Derek Yau, Donna Johnston, Mounira Ibrahim, Maja Krajinovic, Thai Hoa Tran, Jessica Tewfik, Jean‐François Bussières, Thaïna‐Rafi Jean‐Baptiste, Denis Lebel, Lucie Pecheux, Bina Gyawali, Gregory Guilcher, Gesche Riabowol, Geert ’t Jong, Michelle Staub, Geoff Cuvelier, Kathleen Felton, Sara Khalaj, Michael Rieder, Awatif Abuzgaia, Tamorah Lewis, Himal Ghimire, Paul Nathan, Kerry Goralski, Ketan Kulkarni, Zara Forbrigger, Colin J. D. Ross, Bruce C. Carleton +39 morewiley +1 more sourceAnalytical solution of a generalized Penna model
, 2004 In 1995 T.J.Penna introduced a simple model of biological aging. A modified
Penna model has been demonstrated to exhibit behaviour of real-life systems
including catastrophic senescence in salmon and a mortality plateau at advanced
ages.B. Charlesworth, D. Makowiec, J. B. Coe, J.B. Coe, M. Magdon-Maksymowicz, Opinion, P.B. Medawar, P.F. Verhulst, R.M.C. Almeida, R.M.C. Almeida, S. Moss de Oliviera, S.D. Pletcher, T.J.P. Penna, T.J.P. Penna, T.J.P. Penna, W.D. Hamilton, Y. Mao +16 morecore +1 more sourceOutcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose
Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive tumor seen in young children. The optimal timing of resection for locally advanced tumors is not well‐defined. The purpose of this study is to evaluate modern oncologic outcomes and the impact of surgical timing. Methods
A multicenter retrospective review was performed Hannah N. Rinehardt, Elisabeth T. Tracy, Anghela Paredes, Catherine Beckhorn, Harold J. Leraas, Joseph Fusco, Katlyn G. McKay, Nelly‐Ange T. Kontchou, Zachary J. Kastenberg, David W. Hoyt, Jonathan Roach, Emily K. Myers, Nicholas G. Cost, Bhargava Mullapudi, Charles R. Marchese, Amanda R. Jensen, Timothy B. Lautz, Michela Carter, Roshni Dasgupta, John Lundstedt, Joseph G. Brungardt, Lindsay Talbot, Andrew M. Davidoff, Andrew J. Murphy, Jennifer H. Aldrink, Sara Mansfield, Nelson Piche, Annie Le‐Nguyen, Dave R. Lal, Brian T. Craig, Jennifer M. Schuh, Barrett P. Cromeens, Sindhu Mannava, Shannon Castle, Adriana Lopez, Kelsey Mello, Joshua Short, Robin T. Petroze, Shay Rajaval, Grace R. Thompson, Peter Mattei, David H. Rothstein, Elizabeth Fialkowski, Kathryn Fowler, Nathan Martchenke, Barrie S. Rich, Richard D. Glick, Erin G. Brown, Kathleen Doyle, Paige Abril, Natashia Seemann, Jacob Davidson, Claire A. Wilson, Hau D. Le, Devashish Joshi, Michael Stellon, Tamer Ahmed, Alexandra Dimmer, Peter F. Ehrlich, Maya Hammoud, Keyonna Williams, Christa N. Grant, Merit Gorgy, Stephanie F. Polites, Julia Debertin, Danielle B. Cameron, Alyssa Stetson, Eugene S. Kim, William G. Lee, Aaron Barkhordar, Mary Austin, Brian A. Coakley, Anastasia Kahan, Joseph T. Murphy, Michael Pitonak, Chloé Boehmer, Marcus M. Malek +76 morewiley +1 more source
